Allopurinol and the risk of atrial fibrillation in the elderly: A study using medicare data

Annals of the Rheumatic Diseases

Volumn 76, Issue 1, 2017, Pages 72-78

  Singh, Jasvinder A ^a,b,c   Yu, Shaohua ^b  

^a BIRMINGHAM VA MEDICAL CENTER   (United States)

^b University of Alabama at Birmingham   (United States)

^c Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOPURINOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ANTIGOUT AGENT;

AGE; AGED; ARTICLE; CHARLSON ROMANO COMORBIDITY INDEX; COMORBIDITY ASSESSMENT; DRUG USE; FEMALE; GOUT; HUMAN; HYPERURICEMIA; MAJOR CLINICAL STUDY; MALE; MEDICARE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RACE; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SEX; VERY ELDERLY; ADMINISTRATIVE CLAIMS (HEALTH CARE); ATRIAL FIBRILLATION; COMORBIDITY; INCIDENCE; RETROSPECTIVE STUDY; RISK FACTOR; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADMINISTRATIVE CLAIMS, HEALTHCARE; ADRENERGIC BETA-ANTAGONISTS; AGE FACTORS; AGED; AGED, 80 AND OVER; ALLOPURINOL; ATRIAL FIBRILLATION; COMORBIDITY; FEMALE; GOUT SUPPRESSANTS; HUMANS; INCIDENCE; MALE; MEDICARE; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84973293272     PISSN: 00034967     EISSN: 14682060     Source Type: Journal    
DOI: 10.1136/annrheumdis-2015-209008     Document Type: Article

References (49)

1. Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide epidemiology of atrial fibrillation: A Global Burden of Disease 2010 Study. Circulation 2014;129:837-47.
2. Patel NJ, Deshmukh A, Pant S, et al. Contemporary trends of hospitalization for atrial fibrillation in the United States, 2000 through 2010: implications for healthcare planning. Circulation 2014;129:2371-9.
3. Lee WC, Lamas GA, Balu S, et al. Direct treatment cost of atrial fibrillation in the elderly American population: A Medicare perspective. J Med Econ 2008;11:281-98.
4. Kim MH, Johnston SS, Chu BC, et al. Estimation of total incremental health care costs in patients with atrial fibrillation in the United States. Circ Cardiovasc Qual Outcomes 2011;4:313-20.
5. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol 1998;82:2N-9N.
6. Benjamin EJ, Wolf PA, DAgostino RB, et al. Impact of atrial fibrillation on the risk of death: The Framingham Heart Study. Circulation 1998;98:946-52.
7. Thrall G, Lane D, Carroll D, et al. Quality of life in patients with atrial fibrillation: A systematic review. Am J Med 2006;119:448.e1-19.
8. Wang TJ, Larson MG, Levy D, et al. Temporal relations of atrial fibrillation and congestive heart failure and their joint influence on mortality: The Framingham Heart Study. Circulation 2003;107:2920-5.
9. Chugh SS, Blackshear JL, Shen WK, et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol 2001;37:371-8.
10. Go AS, Hylek EM, Phillips KA, et al. Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001;285:2370-5.
11. Sarawate CA, Brewer KK, Yang W, et al. Gout medication treatment patterns and adherence to standards of care from a managed care perspective. Mayo Clin Proc 2006;81:925-34.
12. Singh JA, Hodges JS, Asch SM. Opportunities for improving medication use and monitoring in gout. Ann Rheum Dis 2009;68:1265-70.
13. Lapenna D, de Gioia S, Ciofani G, et al. Antioxidant activity of allopurinol on copper-catalysed human lipoprotein oxidation. FEBS Lett 1997;409:265-8.
14. Pacher P, Nivorozhkin A, Szabó C. Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 2006;58:87-114.
15. Stull LB, Leppo MK, Szweda L, et al. Chronic treatment with allopurinol boosts survival and cardiac contractility in murine postischemic cardiomyopathy. Circ Res 2004;95:1005-11.
16. Bayram D, Tugrul Sezer M, Inal S, et al. The effects of allopurinol on metabolic acidosis and endothelial functions in chronic kidney disease patients. Clin Exp Nephrol 2015;19:443-9.
17. Butler R, Morris AD, Belch JJ, et al. Allopurinol normalizes endothelial dysfunction in type 2 diabetics with mild hypertension. Hypertension 2000;35:746-51.
18. Doehner W, Schoene N, Rauchhaus M, et al. Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation 2002;105:2619-24.
19. Dogan A, Yarlioglues M, Kaya MG, et al. Effect of long-Term and high-dose allopurinol therapy on endothelial function in normotensive diabetic patients. Blood Press 2011;20:182-7.
20. El Solh AA, Saliba R, Bosinski T, et al. Allopurinol improves endothelial function in sleep apnoea: A randomised controlled study. Eur Respir J 2006;27:997-1002.
21. Szwejkowski BR, Gandy SJ, Rekhraj S, et al. Allopurinol reduces left ventricular mass in patients with type 2 diabetes and left ventricular hypertrophy. J Am Coll Cardiol 2013;62:2284-93.
22. Rekhraj S, Gandy SJ, Szwejkowski BR, et al. High-dose allopurinol reduces left ventricular mass in patients with ischemic heart disease. J Am Coll Cardiol 2013;61:926-32.
23. Noman A, Ang DS, Ogston S, et al. Effect of high-dose allopurinol on exercise in patients with chronic stable angina: A randomised, placebo controlled crossover trial. Lancet 2010;375:2161-7.
24. Goicoechea M, de Vinuesa SG, Verdalles U, et al. Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. Clin J Am Soc Nephrol 2010;5:1388-93.
25. de Abajo FJ, Gil MJ, Rodríguez A, et al. Allopurinol use and risk of non-fatal acute myocardial infarction. Heart 2015;101:679-85.
26. Thanassoulis G, Brophy JM, Richard H, et al. Gout, allopurinol use, and heart failure outcomes. Arch Intern Med 2010;170:1358-64.
27. Dubreuil M, Zhu Y, Zhang Y, et al. Allopurinol initiation and all-cause mortality in the general population. Ann Rheum Dis 2015;74:1368-72.
28. Luk AJ, Levin GP, Moore EE, et al. Allopurinol and mortality in hyperuricaemic patients. Rheumatology (Oxford) 2009;48:804-6.
29. Wei L, Fahey T, Struthers AD, et al. Association between allopurinol and mortality in heart failure patients: A long-Term follow-up study. Int J Clin Pract 2009;63:1327-33.
30. Kok VC, Horng JT, Chang WS, et al. Allopurinol therapy in gout patients does not associate with beneficial cardiovascular outcomes: A population-based matched-cohort study. PLoS ONE 2014;9:e99102.
31. Kuo CF, Grainge MJ, Mallen C, et al. Effect of allopurinol on all-cause mortality in adults with incident gout: propensity score-matched landmark analysis. Rheumatology (Oxford) 2015;54:2145-50.
32. Hernandez FE, Tamariz L, Hare J. Allopurinol decreases the incidence of artial fibrillation in heart failure patients[abstract]. J Am Coll Cardiol 2013;61 (10-S).
33. Tseng VL, Yu F, Lum F, et al. Risk of fractures following cataract surgery in Medicare beneficiaries. JAMA 2012;308:493-501.
34. Wunsch H, Guerra C, Barnato AE, et al. Three-year outcomes for Medicare beneficiaries who survive intensive care. JAMA 2010; 303:849-56.
35. Hernandez I, Zhang Y. Risk of bleeding with dabigatran in 2010-2011 medicare data. JAMA Intern Med 2015;175:1245-7.
36. Deyo RA, Cherkin DC, Ciol MA. Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases. J Clin Epidemiol 1992;45:613-19.
37. Jensen PN, Johnson K, Floyd J, et al. A systematic review of validated methods for identifying atrial fibrillation using administrative data. Pharmacoepidemiol Drug Saf 2012;21(Suppl 1):141-7.
38. Navar-Boggan AM, Rymer JA, Piccini JP, et al. Accuracy and validation of an automated electronic algorithm to identify patients with atrial fibrillation at risk for stroke. Am Heart J 2015;169:39-44.e2.
39. Lin DY, Wei LJ. The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989;84:1074-8.
40. Schotten U, Verheule S, Kirchhof P, et al. Pathophysiological mechanisms of atrial fibrillation: A translational appraisal. Physiol Rev 2011;91:265-325.
41. Hanna N, Cardin S, Leung TK, et al. Differences in atrial versus ventricular remodeling in dogs with ventricular tachypacing-induced congestive heart failure. Cardiovasc Res 2004;63:236-44.
42. Sakabe M, Fujiki A, Sakamoto T, et al. Xanthine oxidase inhibition prevents atrial fibrillation in a canine model of atrial pacing-induced left ventricular dysfunction. J Cardiovasc Electrophysiol 2012;23:1130-5.
43. Beattie CJ, Fulton RL, Higgins P, et al. Allopurinol initiation and change in blood pressure in older adults with hypertension. Hypertension 2014;64: 1102-7.
44. Feig DI, Soletsky B, Johnson RJ. Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: A randomized trial. JAMA 2008;300:924-32.
45. Goicoechea M, Garcia de Vinuesa S, Verdalles U, et al. Allopurinol and progression of CKD and cardiovascular events: long-Term follow-up of a randomized clinical trial. Am J Kidney Dis 2015;65:543-9.
46. Bangalore S, Bhatt DL, Steg PG, et al. β-blockers and cardiovascular events in patients with and without myocardial infarction: post hoc analysis from the CHARISMA trial. Circ Cardiovasc Qual Outcomes 2014;7:872-81.
47. Bangalore S, Parkar S, Grossman E, et al. A meta-Analysis of 94, 492 patients with hypertension treated with beta blockers to determine the risk of new-onset diabetes mellitus. Am J Cardiol 2007;100:1254-62.
48. Bangalore S, Steg G, Deedwania P, et al. beta-Blocker use and clinical outcomes in stable outpatients with and without coronary artery disease. JAMA 2012;308:1340-9.
49. Group PS, Devereaux PJ, Yang H, et al. Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): A randomised controlled trial. Lancet 2008;371:1839-47.